Menu
In-Depth

Drug policies take on less prominence

It wasn’t that long ago when Bud Selig was tagged as “The Steroid Commissioner,” and it was widely assumed that moniker would follow him to the grave. But just barely three years since the public release of the infamous Mitchell Report, the issue has largely receded from public view.

Just three major league players have failed a test for performance-enhancing drugs since the start of the 2009 season, the most prominent being slugger Manny Ramirez, then of the Los Angeles Dodgers. The number of minor leaguers implicated over the same time is more than 160. But in general, there is a growing feeling that baseball’s numerous corrections to its drug policies over the past half-decade are beginning to have their intended effects.

The issue will take on less prominence during the coming labor negotiations compared with prior rounds, in part because both sides have regularly addressed the drug program since the Mitchell Report’s release. In addition to measures calling for a thorough annual review, new substances that become federally banned automatically become prohibited within baseball’s drug program.

“We’ve been revisiting this topic regularly. That was one of the big positive outcomes of the Mitchell Report,” said Rob Manfred, MLB executive vice president for labor relations and human resources. “So, yes, it’s fair to say, this one relative to some other issues on the table will not be as major.”

Human growth hormone, however, is still a particularly thorny problem. A scientifically validated and scalable urine test for HGH remains elusive, despite plenty of attention and money, including from MLB, being thrown at the problem.

MLB last year began a blood test for HGH in the minors, where there is no players union and such matters are not subject to collective bargaining, and it’s likely the issue will be at least discussed for the major league level. The MLBPA, however, has historically shown great resistance to any sort of blood collection for testing purposes, with concerns including player safety and residual effects upon on-field performance.

SBJ Morning Buzzcast: March 18, 2024

Sports Business Awards nominees unveiled; NWSL's historic opening weekend and takeaways from CFP deal

ESPN’s Jay Bilas, BTN’s Meghan McKeown, and a deep dive into AppleTV+’s The Dynasty

On this week’s Sports Media Podcast from the New York Post and Sports Business Journal, ESPN’s Jay Bilas talks all things NCAA. Big Ten Network’s Meghan McKeown shares her insight into the Caitlin Clark craze. The Boston Globe’s Chad Finn chats all things Bean Town. And SBJ’s Xavier Hunter drops in to share his findings on how the NWSL is making a social media push.

Learn more about your ad choices. Visit megaphone.fm/adchoices

SBJ I Factor: Nana-Yaw Asamoah

SBJ I Factor features an interview with AMB Sports and Entertainment Chief Commercial Office Nana-Yaw Asamoah. Asamoah, who moved over to AMBSE last year after 14 years at the NFL, talks with SBJ’s Ben Fischer about how his role model parents and older sisters pushed him to shrive, how the power of lifelong learning fuels successful people, and why AMBSE was an opportunity he could not pass up. Asamoah is 2021 SBJ Forty Under 40 honoree. SBJ I Factor is a monthly podcast offering interviews with sports executives who have been recipients of one of the magazine’s awards.

Shareable URL copied to clipboard!

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

Sorry, something went wrong with the copy but here is the link for you.

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

CLOSE